Drug Trial Radar · NCT05128409
Phase I of XKH001Injection in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
35
Planned (sponsor's estimate)
Start
Mar 7, 2023
Primary completion
Oct 1, 2024
Study completion Dec 1, 2024
Sponsor
- Lead sponsor
- Beijing Kanova Biopharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
XKH001is a recombinant humanized monoclonal IgG1 antibody for subcutaneous injection. XKH001 specifically blocks interleukin-25 from binding to its receptors. To evaluate the safety, tolerability, pharmacokinetics (PK) of single ascending doses of XKH001 injection following subcutaneous administration
Conditions
- Healthy Adults
Interventions
XKH001 InjectionDrug
0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
XKH001Placebo InjectionDrug
1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: from admission to discharge, up to 8 weeks
- Incidence of serious adverse events (SAEs)Time frame: from admission to discharge, up to 8 weeks
- AEs leading to termination of dose escalationTime frame: from admission to discharge, up to 8 weeks
- Reported values and changes from baseline in clinical laboratory investigations (hematology)Time frame: from admission to discharge, up to 8 weeks
- Reported values and changes from baseline in clinical laboratory investigations (serum chemistry)Time frame: from admission to discharge, up to 8 weeks
- Reported values and changes from baseline in clinical laboratory investigations ( urinalysis)Time frame: from admission to discharge, up to 8 weeks
- Reported values and changes from baseline in clinical laboratory investigations ( coagulation)Time frame: from admission to discharge, up to 8 weeks
- vital signs (respiratory rate)Time frame: from admission to discharge, up to 8 weeks
- vital signs (body temperature)Time frame: from admission to discharge, up to 8 weeks
- vital signs (supine blood pressure)Time frame: from admission to discharge, up to 8 weeks
- vital signs (pulse)Time frame: from admission to discharge, up to 8 weeks
- 12-lead electrocardiograms (ECGs)Time frame: from admission to discharge, up to 8 weeks
- maximum serum concentration of XKH001Time frame: from admission to discharge, up to 8 weeks
- time to reach maximum serum concentration of XKH001Time frame: from admission to discharge, up to 8 weeks
- area under the serum concentration versus time curve from time zero to time t of XKH001Time frame: from admission to discharge, up to 8 weeks
- systemic clearance of XKH001Time frame: from admission to discharge, up to 8 weeks
- volume of distribution of XKH001Time frame: from admission to discharge, up to 8 weeks
- terminal half-life of XKH001Time frame: from admission to discharge, up to 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University Phase I Clinical Research Center
Changchun, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.